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BACKGROUND
Serotonin (5-hydroxytryptamine, 5-HT) exerts its multiplicity of physiological effects through an unsurpassed diversity of receptors. Some of these effects are mediated through actions of 5-HT in the central nervous system, whereas 5-HT also has multiple and diverse effects through direct interaction with 5-HT receptors in different parts of the cardiovascular system. 1 In blood vessels 5-HT stimulates sympathetic nerves, the endothelium and vascular smooth muscle cells. 2 Triptans are specifi c anti-migraine drugs generally recommended to patients whose conditions are refractory to analgesics. The therapeutic effect of triptans appears to be induced by activating the serotoninergic 5-HT 1B/1D receptors in the trigeminovascular system causing vasoconstriction of the cerebral vessels and neuronal inhibition. Despite their relative selectivity, the vasoconstrictive activity of triptans also affects peripheral arteries, although to a lesser extent. 3 Triptans differ markedly in terms of their pharmacokinetic and pharmacodynamic properties. Some triptans, such as sumatriptan, are considered to be fast-acting while also possessing greater risk of adverse events. Frovatriptan is one of the newest triptans and its distinct pharmacokinetic and pharmacodynamics profi le reveals a clinical potential due to the long duration of action (half-life is 26h) and low incidence of side effects and drug interactions. The elimination half-life of frovatriptan is fi ve times greater than that of other triptans, while the time to maximum concentration is similar to that of other triptans when given orally. 4 It has high affi nity to 5-HT 1B/1D receptors and moderate affi nity to 5-HT 7 receptors. It does not inhibit or induce cytochrome P450, associate to a low rate binding to plasma proteins, which in turn leads to a lower risk of drug interactions. 5 
AIM
To evaluate the effect of frovatriptan on isolated rat carotid artery.
MATERIALS AND METHODS
Male Wistar rats with initial body weight in the range of 220 to 280 g were provided by the Animal House of Medical University Plovdiv, Bulgaria. The rats were housed in standard laboratory conditions (23-25°C, 50-55% humidity and 12/12h light/dark cycle) and fed with standard commercial food and given water ad libitum. At the beginning of the experiments the animals were euthanized by overdose anesthesia (ketamine and xylazine). Smooth muscle preparations of a. carotis communis 0.8-1.0 mm wide and 15 mm long were cut. All experiments were carried out according to the guidelines of using laboratory animals in EU-guidelines/EEC Directive of 1986.
Contractile activity of the preparations was registered isometrically using Tenzo detectors (Swema, Sweden). The initial mechanical stress of the preparations reached by the stretch tensosystem is a value corresponding to the tensile force of 10 mN. Krebs solution (pH = 7.4) used for washing the SM preparations was continuously aerated with a gas mixture of 95% O 2 and 5% CO 2 at 37°C. A 60-minute adaptation of tone level of preparations was taken as a starting tone and changes such as contraction or relaxation were compared to it. During the adaptation the Krebs solution changed several times. The drug-caused reactivity of the SM preparations was measured and registered by gain stage Microtechna (the Czech Republic) and recorded using paper recorder (Linseis, Germany).
CHEMICALS AND SOLUTIONS
The following chemicals were used: acetylcholine (Dispersa Baeschlin, Germany); DMSO (Sigma), frovatriptan succinate monohydrate (Sigma), methysergide maleate salt (Sigma), L-norepinephrine hydrochloride (Sigma), prazosin hydrochloride (Sigma).
The Krebs solution had the following composition (mM): NaCl 120; KCl 5.9; CaCl 2 2.5; MgCl 2 1.2; NaH 2 PO 4 1.2; NaHCO 3 15.4 and glucose 11.5 (Merck).
STATISTICS
The data obtained were expressed as mean ± standard error of the mean (SEM). The number of tissue preparations used in each experiment is indicated by n. Statistical differences were tested using the Student's t-test, and P<0.05 was considered significant. All statistical analyses were performed using a specialized software SPSS, version 17.0 (SPSS Inc. Chicago, IL).
RESULTS

EFFECTS OF FROVATRIPTAN ON THE CONTRACTILE ACTIVITY OF SM PREPARATION OF CAROTID ARTERY.
At the concentration of 1×10 -6 mol/l and 1×10 -5 mol/l, frovatriptan induced contraction in the SM preparations of carotid artery (Fig. 1) . At concentrations of 5×10 -5 mol/l and higher frovatriptan provoked signifi cant relaxation (Fig. 2) . In the presence of frovatriptan at a concentration of 5×10 -5 mol/l we observed a signifi cant increase of the contractile reaction of L-norepinephrine (1×10 -5 mol/l) compared to the control reaction (Fig. 3) . Frovatriptan (5×10 -5 mol/l) in the presence of the 5-HT 2 receptor antagonist methysergide (1×10 -5 mol/l) signifi cantly increased the relaxation compared to the control reaction exerted by frovatriptan alone (Fig. 4) . 
EFFECTS OF 5×10 -5 MOL/L FROVATRIPTAN ON THE CON-TRACTILE ACTIVITY OF SM PREPARATIONS OF CAROTID ARTERY IN PRESENCE OF PRAZOSIN.
In the presence of the specifi c alpha-1 receptor antagonist, prazosin (1×10 -6 mol/l), the relaxation induced by frovatriptan (5×10 -5 mol/l) signifi cantly decreased compared to that in the controls by frovatriptan alone (Fig. 5) . 
DISCUSSION
Studies using isolated blood vessels provide a robust quantitative pharmacological comparison of drugs and may identify subtle differences between triptans. These differences are of scientifi c interest since, in theory, all triptans belong to the same class (i.e. 5-HT 1B/1D receptor agonists) and therefore would be expected to have similar pharmacological actions. It is important to remember that any differences detected using in vitro studies should not be extrapolated and used as predictors or comparators of drug effects when administered to man. 5-HT was recognized as a substance isolated from blood serum (sero-) that could modify the tone of smooth muscles (-tonin). [6] [7] [8] Frovatriptan, which belongs to the group of triptans, may act by constricting cranial vessels through 5-HT 1B receptors, by inhibiting peripheral trigeminal nerve afferents that innervate the vessels and pain-producing dura mater through 5-HT 1D receptors, or by inhibiting central trigeminal neuronal traffi c through 5-HT 1D receptors, or by a combination of these mechanisms. 9 Our results shows that at concentrations of 1×10 -6 mol/l and 1×10 -5 mol/l frovatriptan induces contractions in SM preparations of carotid artery. This effect is probably related to the drug's main action -activation of serotoninergic 5-HT 1B/1D receptors causing vasoconstriction of the cerebral vessels and their anti-migraine effect. It is well known that a-adrenoceptors play an important role in the regulation of vascular tone and blood pressure and that stimulation of the receptors mediate constriction of the isolated carotid artery. 10 There are 3 α-1 adrenergic receptor subtypes: α 1A, α 1B, and α 1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. They activate mitogenic responses and regulate growth and proliferation of many cells. Catecholamines like norepinephrine (noradrenaline) and epinephrine (adrenaline) infl uence signaling pathways through the α 1 -adrenergic receptor in the central and peripheral nervous systems. α 1A -and α 1B -ARs localized to the plasma membrane while α 1D -ARs accumulate intracellularly. 11 There is evidence in the literature that the activation of α 1 -adrenoceptors induces relaxation in rabbit bronchial artery 12 and rat pulmonary arteries, in a process involving the endothelial production and release of nitric oxide (NO). In the rat carotid artery, phenylephrine produce an endothelium-dependent relaxation mediated by α 1D adrenoreceptors and involving the endothelial NO synthase (eNOS). 13 Frovatriptan possesses higher 5-HT 1B agonist affi nity and less affi nity to α 1D adrenoreceptors. Our experiment showed that in its lower concentration frovatriptan occupied by priority 5-HT 1B receptors, and only then the NO activation pathway of α 1D receptors could be possible. After all this a smooth muscle contraction is observed in the 1×10 -6 mol/l and 1×10 -5 mol/l drug concentrations.
Despite the drug's lower α 1 -adrenoreceptor affi nity in higher concentrations, it could be balanced under the following intracellular pathway: activation of α 1D -ARs -NO synthesis -guanylate cyclase activation -increasing of internal cGMP -activation of protein kinase G (PKG). On the one hand PKG could infl uence directly the contractile machinery of smooth muscles 14 , on the other hand it could block L-type Ca 2+ channels (in terms of Ca 2+ infl ux reduction, necessary for muscle contraction) 15 and on third hand PKG could activate calcium pumps whish also leads to reduction of intracellular calcium. The overall processes cumulation leads to 5-HT 1B and α 1D activation and subsequent smooth muscle relaxation at a concentration of 5×10 -5 mol/l of frovatriptan.
Such a hypothesis is supported by the results of experiments conducted with methysergide (specifi c inhibitor (5HT) receptor) and prazosin (specifi c inhibitor of alpha-1 receptors). Our data shows that the block 5-HT receptors by methysergide is probably due to activation of the α 1D receptors by frovatriptan.
The blockade of α 1 receptors by prazosin reduced signifi cantly the frovatriptan-induced relaxation which confi rms the probable involvement of α 1D receptors in the realization of its effects. As a result of experiments conducted in the presence of frovatriptan (5×10 -5 mol/l), the contractile response to L-norepinephrine was signifi cantly increased compared to control reaction on the carotid artery. Our results also suggest that frovatriptan predominantly at higher concentrations probably by non-specifi c mechanism, which could activate the following intracellular chain reaction: stimulation on α 1D → activation of eNOS → increase in the concentration of NO 16 and subsequent relaxation, which is atypical for the triptans.
In conclusion, frovatriptan in concentrations of 1×10 -6 mol/l, 1×10 -5 mol/l induces contractions in the carotid artery which is due to the activation of 5-HT 1B / D receptors. At higher concentrations (5×10 -5 mol/l) frovatriptan induces relaxation atypical for triptans. This effect could be a result from the activation of α 1D receptors. On the other hand, at a concentration of 5×10 -5 mol/l frovatriptan potentiates the effect of L-norepinephrine which in turn can activate the following intracellular cascade: stimulation of α 1D receptors followed by activation of eNOS and subsequently increased concentration of NO with the fi nal effect of relaxation.
Apparently frovatriptan initiates very complicated and balanced pathways via 5-HT 1B and α 1D receptors, which, depending on its concentration, could lead to contraction or relaxation of the carotid artery.
